

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Auto-R ply Facsimile Transmission



TO:

Fax Sender at 1 858 720 2555

Fax Information

Date Received:

Total Pages:

12/16/2003 8:36:58 PM [Eastern Standard Time]
54 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page
=====>

Paul Hastings

FACSIMILE TRANSMISSION

from:	to:	telephone:	initials:
Diana L. Bush, Ph.D., Esq.	(858) 720-2555	(858) 720-2555	DLB

client name: Mochales Thompson, Inc. client matter: 45198.00013.RCB
date: December 16, 2003
pages (with cover): 54

to:	company/office:	facsimile:	telephone:
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	USPTO Group A et Unit 1624	703 872-9306	703 306-9806

U. S. Patent Application No. 09/518,501
NOVEL PHOSPHORUS-CONTAINING PRODRUGS
Applicant: Elian et al.
Filing Date: March 3, 2000
Our Ref: 45198.00013.RCB

- Attached hereto are the following documents for filing in the above patent application:
1. For Transmittal Sheet
 2. Petition for Extension of Time & Response
 3. Interview Summary
 4. Extended Declaration of John C. Chabala Pursuant to 37 C.F.R. § 1.132

CERTIFICATE OF TRANSMISSION (37 C.F.R. § 1.9)

I hereby certify that this paper (along with anything referred to as being included or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

December 16, 2003
Date of Transmission

Kimberly Chenery
Name of Person Transmitting Paper
Signature of Person Transmitting Paper

If you do not receive all pages, please call immediately Facsimile Center: (858) 720-2555

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential, conditional and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

Paul, Hastings, Janofsky & Walker LLP
3579 Valley Centre Drive, San Diego, CA 92130
telephone 858-720-2500 / facsimile 858-720-2555 / www.paulhastings.com

Paul Hastings

FACSIMILE TRANSMISSION

from: Diana L. Bush, Ph.D., Esq. **facsimile:** (858) 720-2555 **telephone:** (858) 720-2885 **initials:** DLB4
client name: Metabasis Therapeutics, Inc. **client matter number:** 45198.00013.RCE
date: December 17, 2003 **pages (with cover):** 54

to: Examiner Thomas McKenzie, Ph.D.
Art Unit 1624 **company/office:** USPTO **facsimile:** 703 746-3152 **telephone:** 703 308-9806

comments: Courtesy copy as per Examiner's request at the September 10, 2003 interview (Original faxed December 16, 2003).

U. S. Patent Application No. 09/518,501
NOVEL PHOSPHORUS-CONTAINING PRODRUGS
Applicant: Erion et al.
Filing Date: March 3, 2000
Our Ref: 45198.00013.RCE

Attached hereto are the following documents for filing in the above patent application:

1. Fee Transmittal Sheer
2. Petition for Extension of Time & Response
3. Interview Summary
4. Executed Declaration of John C. Chabala Pursuant to 37 C.F.R. § 1.132

CERTIFICATE OF TRANSMISSION
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Kimila Carraway
Name of Person Transmitting Paper

December 16, 2003
Date of Transmission

Signature of Person Transmitting Paper

If you do not receive all pages, please call immediately Facsimile Center: (858) 720-2903

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

Paul, Hastings, Janofsky & Walker LLP
3579 Valley Centre Drive, San Diego, CA 92130
telephone 858-720-2500 / facsimile 858-720-2555 / www.paulhastings.com

PaulHastings

FACSIMILE TRANSMISSION

from:	facsimile:	telephone:	Initials:
Diana L. Bush, Ph.D., Esq.	(858) 720-2555	(858) 720-2885	DLB4
client name: Metabasis Therapeutics, Inc.	client matter	45198.00013.RCE	
date: December 16, 2003	number:		
	pages (with cover):	56 <u>54</u>	

to:	company/office:	facsimile:	telephone:
Commissioner for Patents	USPTO	703 872-9306	703 308-9806
P.O. Box 1450	Group Art Unit		
Alexandria, VA 22313-1450	1624		

comments:

U. S. Patent Application No. 09/518,501
NOVEL PHOSPHORUS-CONTAINING PRODRUGS
Applicant: Erion et al.
Filing Date: March 3, 2000
Our Ref: 45198.00013.RCE

Attached hereto are the following documents for filing in the above patent application:

1. Fee Transmittal Sheet
2. Petition for Extension of Time & Response
3. Interview Summary
4. Executed Declaration of John C. Chabala Pursuant to 37 C.F.R. § 1.132

CERTIFICATE OF TRANSMISSION
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

December 16, 2003
Date of Transmission

Kimila Carraway

Name of Person Transmitting Paper

Kimila Carraway
Signature of Person Transmitting Paper

If you do not receive all pages, please call immediately Facsimile Center: (858) 720-2903

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

Paul, Hastings, Janofsky & Walker LLP
 3579 Valley Centre Drive, San Diego, CA 92130
 telephone 858-720-2500 / facsimile 858-720-2555 / www.paulhastings.com

PaulHastings

FACSIMILE TRANSMISSION

from: Diana L. Bush, Ph.D., Esq. facsimile: (858) 720-2555 telephone: (858) 720-2885 initials: DLB4

client name: Metabasis Therapeutics, Inc. client matter number: 45198.00013.RCE

date: January 26, 2004

pages (with cover): 60 (61)

to: Examiner Mukund Shah company/office: USPTO facsimile: 703 308-4734 telephone: 703 308-4716
 Art Unit 1624

comments: **Copy of Response to Office Action mailed June 16, 2003, as originally faxed on December 16, 2003.**

U. S. Patent Application No. 09/518,501
NOVEL PHOSPHORUS-CONTAINING PRODRUGS

Applicant: Erion et al.
 Filing Date: March 3, 2000
 Our Ref: 45198.00013.RCE

Attached hereto are the following documents for filing in the above patent application:

1. Copies of facsimile transmittal sheet, transmission report and USPTO auto-reply facsimile transmission report
2. Copy of Fee Transmittal Sheet
3. Copy of Petition for Extension of Time & Response
4. Copy of Interview Summary
5. Copy of Executed Declaration of John C. Chabala Pursuant to 37 C.F.R. § 1.132

CERTIFICATE OF TRANSMISSION
 (37 C.F.R. § 1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Kimila Carraway
 Name of Person Transmitting Paper

December 16, 2003
 Date of Transmission

 Signature of Person Transmitting Paper

If you do not receive all pages, please call immediately Facsimile Center: (858) 720-2903

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

PTO/SB/17 (11-00)

Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2003

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$750.00)

Complete if Known

Application Number	09/518,501
Filing Date	December 16, 2003
First Named Inventor	Erion et al.
Examiner Name	McK nzie, T.
Group Art Unit	1624
Attorney Docket No.	45198.00013.RCE

METHOD OF PAYMENT

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **50-2613**

Deposit Account Name

- ☒
- Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
-
- ☐
- Applicant claims small entity status. See 37 CFR 1.27

Charge fee(s)

- 2.
- ☒
- Indicated below:

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$0)

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid	
1	-20**	X	0	
Independent Claims	1	-3**	X	0

Multiple Dependent

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1202	18	2202	9	Claims in excess of 20	
1201	84	2201	42	Independent claims in excess of 3	
1203	280	2203	140	Multiple dependent claim, if not paid	
1204	84	2204	42	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$0)

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	\$475.00
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$475.00)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Diana L. Bush, Ph.D., Esq.	Registration No. (Attorney/Agent)	51,109	Telephone	(858) 720-2500
Signature	<i>Diana L. Bush</i>	Date	12/16/03		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.